Why the study?
Does CYP2C19 loss-of-function allele carrier status increase the risk of stroke and composite vascular events in patients with ischemic stroke or TIA treated with clopidogrel?
Population
Patients with ischemic stroke or transient ischemic attack (TIA) treated with clopidogrel
Comparison
Clopidogrel therapy in carriers of CYP2C19… vs Clopidogrel therapy in noncarriers of CYP2C19…
Design
Other
Authors
Loading...
May warrant CYP2C19 testing to identify clopidogrel nonresponders post-stroke; leaves open randomized confirmation of genotype-guided therapy.
Does CYP2C19 loss-of-function allele carrier status increase the risk of stroke and composite vascular events in patients with ischemic stroke or TIA treated with clopidogrel?
CYP2C19 loss-of-function allele carriers have reduced clopidogrel efficacy, leading to a higher risk of recurrent stroke and vascular events after an ischemic stroke or TIA.
Pan et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: